Imarsa (Fulvestrant)

Fulvestrant binds to the ligand‑binding domain of estrogen receptors with high affinity, causing the receptors to be tagged for degradation by the proteasome. This reduces intracellular estrogen receptor levels, blocking estrogen‑mediated transcription and slowing the proliferation of ER‑positive cancer cells.

The dosing regimen for Imarsa is determined by the prescribing clinician based on the patient’s clinical condition, treatment history and regulatory guidelines. It is administered as an intramuscular injection, and the prescriber decides the dose, frequency and duration of therapy.

The safety of fulvestrant in pregnancy and lactation has not been established. It is classified as unknown for pregnancy, and use is generally avoided in pregnant or nursing women. Effective contraception is recommended for women of child‑bearing potential during treatment.

To request Imarsa, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Imarsa (fulvestrant) is a SERD that degrades estrogen receptors, whereas aromatase inhibitors reduce estrogen production. Fulvestrant offers a different mechanism useful after resistance to aromatase inhibitors or tamoxifen. Compared with newer oral SERDs, Imarsa is administered by injection, which may affect convenience but provides reliable systemic exposure.

Imarsa should be stored at 2‑8 °C (refrigerated), protected from light, and must not be frozen or shaken. The product should remain in its original packaging until use to maintain stability and potency.

Imarsa is given as a deep intramuscular injection, typically into the gluteal muscle or thigh, by a qualified healthcare professional. The injection is performed under aseptic conditions, and the prescribed dosing schedule is followed as directed by the treating physician.

Serious adverse events associated with Imarsa include hepatotoxicity, thromboembolic events (such as deep‑vein thrombosis or pulmonary embolism), interstitial lung disease, severe allergic reactions, and QT‑interval prolongation. Patients should be monitored regularly for signs of liver dysfunction, clotting disorders, respiratory symptoms and cardiac abnormalities.

Imarsa is contraindicated in patients with known hypersensitivity to fulvestrant or any excipients in the formulation. It should also be avoided in individuals with severe hepatic impairment, uncontrolled cardiac disease, or in women who are pregnant or breastfeeding. Clinicians must assess each patient’s medical history before initiating therapy.